NA
AKBA icon

NewEdge Advisors’s Akebia Therapeutics AKBA Stock Holding History

NewEdge Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,535
Closed -$2.59K – 3808
2024
Q2 		$2.59K Hold
2,535
– – ﹤0.01% 3284
2024
Q1 		$4.64K Hold
2,535
– – ﹤0.01% 3158
2023
Q4 		$3.14K Hold
2,535
– – ﹤0.01% 3249
2023
Q3 		$2.89K Hold
2,535
– – ﹤0.01% 2964
2023
Q2 		$2.32K Sell
2,535
-800
-24% -$772 ﹤0.01% 3049
2023
Q1 		$1.87K Hold
3,335
– – ﹤0.01% 3047
2022
Q4 		$2 Buy
+3,335
New +$1.04K ﹤0.01% 3923

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewEdge Advisors's AKBA Position: Q3 2024 in Review

NewEdge Advisors sold out of Akebia Therapeutics (AKBA) in Q3 2024, closing a stake of 2,535 shares — an estimated $2.59K sold.

NewEdge Advisors first reported a position in AKBA in Q4 2022 and held it in 7 quarters. The position peaked at $4.64K in Q1 2024. 114 funds tracked by Wall St. Rank hold AKBA as of Q3 2024.

  • NewEdge Advisors reported no remaining Akebia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • NewEdge Advisors sold 2,535 Akebia Therapeutics shares in Q3 2024, an estimated $2.59K.
  • NewEdge Advisors first reported a position in Akebia Therapeutics in Q4 2022 and held it in 7 quarters.
  • NewEdge Advisors's Akebia Therapeutics position peaked at $4.64K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.